

**REMARKS**

Claims 13-25 are now pending, with claim 13 being the sole independent claim.

Claims 1-12 have been canceled without prejudice to or disclaimer of the subject matter recited therein.

Claims 13-25 have been added. Support for the sequence identities recited in claims 13-25 is found at least in the paragraph at page 6, lines 13-27, of the specification. Support for the use of the term "recombinant" in claims 19, 21, 23 and 24 is found at least in the paragraph at page 10, lines 26-29, of the specification. Support for claims 22-24 are found at least in Examples 4-5, pages 18-22 of the specification. No new matter has been added.


**RESPONSE TO RESTRICTION REQUIREMENT**

In response to the Restriction Requirement in the Office Action mailed July 26, 2002, Applicants hereby elect, without traverse, Group III, claims 1-5, and 7, drawn to the nucleic acid of SEQ ID NO:5, a chimeric gene comprising the nucleic acid, a host cell comprising the chimeric gene, and a method of use of the chimeric gene, classified in class 536, subclass 23.2. Applicants submit that now pending Claims 13-25 are directed to Group III, concerning SEQ ID NO:5 or a nucleic acid sequence encoding SEQ ID NO:6.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,



J. KENNETH JOUNG  
Attorney For Applicants  
Registration No. 41,881  
Telephone: 302-992-4929  
Facsimile: 302-892-1026

Dated: 30 December 2002